{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:57:59Z","timestamp":1761897479579,"version":"3.44.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jns.2021.117335","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T02:09:16Z","timestamp":1613527756000},"page":"117335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Polyneuropathy and monoclonal gammopathy of undetermined significance (MGUS); update of a clinical experience"],"prefix":"10.1016","volume":"423","author":[{"given":"Sabrina","family":"Mat\u00e0","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Torricelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Barilaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonello","family":"Grippo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Forleo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Del Mastio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Sorbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2021.117335_bb0005","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","author":"Kyle","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jns.2021.117335_bb0010","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1600-0404.1992.tb06033.x","article-title":"Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies","volume":"85","author":"Nobile-Orazio","year":"1992","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jns.2021.117335_bb0015","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.54.3.615","article-title":"Distal acquired demyelinating symmetric neuropathy","author":"Katz","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2021.117335_bb0020","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/123.4.710","article-title":"Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies","author":"Nobile-Orazio","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.jns.2021.117335_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2014.01.012","article-title":"Prevalence, specificity and functionality of anti-ganglioside antibodies in neuropathy associated with IgM monoclonal gammopathy","author":"Stork","year":"2014","journal-title":"J. Neuroimmunol."},{"issue":"5","key":"10.1016\/j.jns.2021.117335_bb0030","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/WCO.0000000000000726","article-title":"Neuropathies and paraproteins","volume":"32","author":"Lunn","year":"2019","journal-title":"Curr. Opin. Neurol."},{"issue":"8","key":"10.1016\/j.jns.2021.117335_bb0035","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1468-1331.2010.03345.x","article-title":"IgM monoclonal gammopathy-associated neuropathies with different IgM specificity","volume":"18","author":"Mat\u00e0","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2021.117335_bb0040","doi-asserted-by":"crossref","DOI":"10.1111\/j.1468-1331.2009.02930.x","article-title":"European federation of neurological societies\/peripheral nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripher","author":"Van Den Bergh","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2021.117335_bb0045","doi-asserted-by":"crossref","DOI":"10.1002\/ana.410240113","article-title":"A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside","author":"Pestronk","year":"1988","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2021.117335_bb0050","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617746640","article-title":"Advances in the diagnosis, immunopathogenesis and therapies of igm-anti-mag antibody-mediated neuropathies","author":"Dalakas","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jns.2021.117335_bb0055","doi-asserted-by":"crossref","DOI":"10.1007\/BF00294374","article-title":"Polyneuropathy associated with IgM monoclonal gammopathy - immunological and pathological study in 31 patients","author":"Vital","year":"1989","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.jns.2021.117335_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinph.2018.07.021","article-title":"Anti-MAG neuropathy: role of IgM antibodies, the paranodal junction and juxtaparanodal potassium channels","author":"Garg","year":"2018","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.jns.2021.117335_bb0065","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/117.5.941","article-title":"Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside","author":"Kaku","year":"1994","journal-title":"Brain"},{"key":"10.1016\/j.jns.2021.117335_bb0070","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2017-316715","article-title":"Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features","author":"Svahn","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2021.117335_bb0075","doi-asserted-by":"crossref","DOI":"10.1111\/ene.13459","article-title":"Prevalence, correlates and impact of pain and cramps in anti-MAG neuropathy: a multicentre European study","author":"Rajabally","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2021.117335_bb0080","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.45.4.827","article-title":"Autopsy-proven amyotrophic lateral sclerosis, Waldenstr\u00f6m\u2019s macroglobulinemia, and antibodies to sulfated glucuronic acid paragloboside","author":"Rowland","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2021.117335_bb0085","doi-asserted-by":"crossref","DOI":"10.1007\/s10072-019-04089-7","article-title":"Anti-MAG IgM: differences in antibody tests and correlation with clinical findings","author":"Mat\u00e0","year":"2020","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jns.2021.117335_bb0090","doi-asserted-by":"crossref","DOI":"10.1007\/s10072-017-3133-0","article-title":"Chronic demyelinating neuropathy with anti-myelin-associated glycoprotein antibody without any detectable M-protein","author":"Sakamoto","year":"2017","journal-title":"Neurol. Sci."},{"issue":"10","key":"10.1016\/j.jns.2021.117335_bb0095","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.57.10.1909","article-title":"Antiganglioside antibodies in polyneuropathy associated with monoclonal gammopathy","volume":"57","author":"Eurelings","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2021.117335_bb0100","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-018-8853-4","article-title":"CANOMAD and other chronic ataxic neuropathies with disialosyl antibodies (CANDA)","author":"Garcia-Santibanez","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2021.117335_bb0105","doi-asserted-by":"crossref","DOI":"10.1002\/mus.24192","article-title":"Acute and chronic ataxic neuropathies with disialosyl antibodies: A continuous clinical spectrum and a common pathophysiological mechanism","author":"Yuki","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2021.117335_bb0110","doi-asserted-by":"crossref","DOI":"10.1111\/jns.12359","article-title":"Myelin uncompaction and axo-glial detachment in chronic ataxic neuropathy with monospecific IgM antibody to ganglioside GD1b","author":"Tagliapietra","year":"2020","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.jns.2021.117335_bb0115","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-014-7612-4","article-title":"Association of IgM monoclonal gammopathy with progressive muscular atrophy and multifocal motor neuropathy: A case\u2013control study","author":"Vlam","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2021.117335_bb0120","article-title":"IgM-gammopathy strongly favours immune treatable MMN and MADSAM over ALS","author":"Shelly","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2021.117335_bb0125","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp.72.6.761","article-title":"Multifocal motor neuropathy: Clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block","author":"Nobile-Orazio","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2021.117335_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2009.04.013","article-title":"Beneficial effect of rituximab monotherapy in multifocal motor neuropathy","author":"Stieglbauer","year":"2009","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.jns.2021.117335_bb0135","doi-asserted-by":"crossref","DOI":"10.1111\/j.1529-8027.2010.00270.x","article-title":"An open-label trial of rituximab (Rituxan\u00ae) in multifocal motor neuropathy","author":"Chaudhry","year":"2010","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.jns.2021.117335_bb0140","doi-asserted-by":"crossref","DOI":"10.1002\/mus.26051","article-title":"Composite ganglioside autoantibodies and immune treatment response in MMN and MADSAM","author":"Martinez-Thompson","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2021.117335_bb0145","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000720","article-title":"The Bruton tyrosine kinase ibrutinib improves anti-MAG antibody polyneuropathy","author":"Castellani","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21000289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21000289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:53:17Z","timestamp":1758383597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X21000289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":29,"alternative-id":["S0022510X21000289"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2021.117335","relation":{},"ISSN":["0022-510X"],"issn-type":[{"type":"print","value":"0022-510X"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polyneuropathy and monoclonal gammopathy of undetermined significance (MGUS); update of a clinical experience","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2021.117335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117335"}}